放疗联合免疫治疗在头颈部鳞状细胞癌治疗中的应用

doi:10.3760/cma.j.cn371439-20230612-00105

摘要/Abstract

摘要：

免疫检查点抑制剂在头颈部鳞状细胞癌（HNSCC）的治疗中已显示出显著的临床获益。有研究表明放疗联合免疫治疗可产生协同效应，同时多项Ⅰ/Ⅱ期临床研究提示放疗联合免疫治疗在局部晚期HNSCC中具有良好的安全性和初步疗效获益，然而二者联合治疗的时机、放疗剂量/分割模式的选择及获益人群的筛选尚无明确定论。进一步探讨放疗联合免疫治疗在HNSCC治疗中的增效机制、临床研究现状及面临的挑战，旨在指导HNSCC的临床实践、改善患者预后。

关键词: 头颈部肿瘤, 癌，鳞状细胞, 放射疗法, 免疫疗法

Abstract:

Immune checkpoint inhibitors in the treatment of head and neck squamous cell carcinoma （HNSCC） has shown significant clinical benefit. Some studies have shown that radiotherapy combined with immunotherapy can produce synergistic effects， and several phase Ⅰ/Ⅱ clinical trials have suggested that radiotherapy combined with immunotherapy has good safety and preliminary efficacy benefits in locally advanced HNSCC. However， the timing of combination therapy， the selection of radiotherapy dose/fractionation mode and patients are still unclear. This article further discusses the synergistic mechanism， clinical research status and challenges of radiotherapy combined with immunotherapy in the treatment of HNSCC， aiming to guide the clinical practice and improve the prognosis of HNSCC patients.

Key words: Head and neck neoplasms, Carcinoma， squamous cell, Radiotherapy, Immunotherapy

崔腾璐, 吕璐, 孙鹏飞. 放疗联合免疫治疗在头颈部鳞状细胞癌治疗中的应用[J]. 国际肿瘤学杂志, 2023, 50(9): 548-552.

Cui Tenglu, Lyu lu, Sun Pengfei. Application of radiotherapy combined with immunotherapy in the treatment of head and neck squamous cell carcinoma[J]. Journal of International Oncology, 2023, 50(9): 548-552.

参考文献 41

[1]	Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021[J]. CA Cancer J Clin, 2021, 71(1): 7-33. DOI: 10.3322/caac.21654.
[2]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
[3]	Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study[J]. Lancet, 2019, 394(10212): 1915-1928. DOI: 10.1016/S0140-6736(19)32591-7. pmid: 31679945
[4]	Borel C, Jung AC, Burgy M. Immunotherapy breakthroughs in the treatment of recurrent or metastatic head and neck squamous cell carcinoma[J]. Cancers (Basel), 2020, 12(9): 2691. DOI: 10.3390/cancers12092691.
[5]	Sato Y, Fukuda N, Wang X, et al. Efficacy of nivolumab for head and neck cancer patients with primary sites and histological subtypes excluded from the CheckMate-141 trial[J]. Cancer Manag Res, 2020, 12: 4161-4168. DOI: 10.2147/CMAR.S249393. pmid: 32581587
[6]	Muzaffar J, Bari S, Kirtane K, et al. Recent advances and future directions in clinical management of head and neck squamous cell carcinoma[J]. Cancers (Basel), 2021, 13(2): 338. DOI: 10.3390/cancers13020338.
[7]	Wang H, Lin X, Luo Y, et al. α-PD-L1 mAb enhances the abscopal effect of hypo-fractionated radiation by attenuating PD-L1 expression and inducing CD8⁺ T-cell infiltration[J]. Immunotherapy, 2019, 11(2): 101-118. DOI: 10.2217/imt-2018-0049. pmid: 30511887
[8]	Rodríguez-Ruiz ME, Vanpouille-Box C, Melero I, et al. Immunological mechanisms responsible for radiation-induced abscopal effect[J]. Trends Immunol, 2018, 39(8): 644-655. DOI: 10.1016/j.it.2018.06.001. pmid: 30001871
[9]	Barsoumian HB, He K, Hsu E, et al. NLRP3 agonist enhances radiation-induced immune priming and promotes abscopal responses in anti-PD1 resistant model[J]. Cancer Immunol Immunother, 2023, 72(9): 3003-3012. DOI: 10.1007/s00262-023-03471-x.
[10]	Lhuillier C, Rudqvist NP, Yamazaki T, et al. Radiotherapy-exposed CD8⁺ and CD4⁺ neoantigens enhance tumor control[J]. J Clin Invest, 2021, 131(5): e138740. DOI: 10.1172/JCI138740.
[11]	Shi C, Qin K, Lin A, et al. The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy[J]. J Exp Clin Cancer Res, 2022, 41(1): 268. DOI: 10.1186/s13046-022-02469-0. pmid: 36071479
[12]	Monjazeb AM, Schalper KA, Villarroel-Espindola F, et al. Effects of radiation on the tumor microenvironment[J]. Semin Radiat Oncol, 2020, 30(2): 145-157. DOI: 10.1016/j.semradonc.2019.12.004. pmid: 32381294
[13]	Patin EC, Dillon MT, Nenclares P, et al. Harnessing radiotherapy-induced NK-cell activity by combining DNA damage-response inhibition and immune checkpoint blockade[J]. J Immunother Cancer, 2022, 10(3): e004306. DOI: 10.1136/jitc-2021-004306.
[14]	Choi JS, Sansoni ER, Lovin BD, et al. Abscopal effect following immunotherapy and combined stereotactic body radiation therapy in recurrent metastatic head and neck squamous cell carcinoma: a report of two cases and literature review[J]. Ann Otol Rhinol Laryngol, 2020, 129(5): 517-522. DOI: 10.1177/0003489419896602.
[15]	Wu JS, Jen CW, Chen HH, et al. Stereotactic body radiotherapy and checkpoint inhibitor for locally recurrent unresectable nasopharyngeal carcinoma[J]. BMJ Case Rep, 2021, 14(7): e240806. DOI: 10.1136/bcr-2020-240806.
[16]	Powell SF, Gold KA, Gitau MM, et al. Safety and efficacy of pembrolizumab with chemoradiotherapy in locally advanced head and neck squamous cell carcinoma: a phase ⅠB study[J]. J Clin Oncol, 2020, 38(21): 2427-2437. DOI: 10.1200/JCO.19.03156.
[17]	Gillison ML, Ferris RL, Harris J, et al. Safety of nivolumab added to chemoradiation therapy platforms for intermediate and high-risk locoregionally advanced head and neck squamous cell carcinoma: RTOG foundation 3504[J]. Int J Radiat Oncol Biol Phys, 2023, 115(4): 847-860. DOI: 10.1016/j.ijrobp.2022.10.008.
[18]	Bauman JE, Harris J, Uppaluri R, et al. NRG-HN003: phase Ⅰ and expansion cohort study of adjuvant pembrolizumab, cisplatin and radiation therapy in pathologically high-risk head and neck cancer[J]. Cancers (Basel), 2021, 13(12): 2882. DOI: 10.3390/cancers13122882.
[19]	Weiss J, Sheth S, Deal AM, et al. Concurrent definitive immunoradiotherapy for patients with stage Ⅲ-Ⅳ head and neck cancer and cisplatin contraindication[J]. Clin Cancer Res, 2020, 26(16): 4260-4267. DOI: 10.1158/1078-0432.CCR-20-0230.
[20]	Tao Y, Biau J, Sun XS, et al. Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase Ⅱ trial[J]. Ann Oncol, 2023, 34(1): 101-110. DOI: 10.1016/j.annonc.2022.10.006.
[21]	McBride S, Sherman E, Tsai CJ, et al. Randomized phase Ⅱ trial of nivolumab with stereotactic body radiotherapy versus nivolumab alone in metastatic head and neck squamous cell carcinoma[J]. J Clin Oncol, 2021, 39(1): 30-37. DOI: 10.1200/JCO.20.00290.
[22]	Yu Y, Lee NY. JAVELIN head and neck 100: a phase Ⅲ trial of avelumab and chemoradiation for locally advanced head and neck cancer[J]. Future Oncol, 2019, 15(7): 687-694. DOI: 10.2217/fon-2018-0405.
[23]	Machiels JP, Tao Y, Burtness B, et al. Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412[J]. Future Oncol, 2020, 16(18): 1235-1243. DOI: 10.2217/fon-2020-0184.
[24]	Wong KCW, Johnson D, Hui EP, et al. Opportunities and challenges in combining immunotherapy and radiotherapy in head and neck cancers[J]. Cancer Treat Rev, 2022, 105: 102361. DOI: 10.1016/j.ctrv.2022.102361.
[25]	Mirestean CC, Iancu RI, Iancu DT. Immunotherapy and radiotherapy as an antitumoral long-range weapon—a partnership with unsolved challenges: dose, fractionation, volumes, therapeutic sequence[J]. Curr Oncol, 2022, 29(10): 7388-7395. DOI: 10.3390/curroncol29100580.
[26]	Rajeev-Kumar G, Pitroda SP. Synergizing radiotherapy and immunotherapy: current challenges and strategies for optimization[J]. Neoplasia, 2023, 36: 100867. DOI: 10.1016/j.neo.2022.100867.
[27]	Arina A, Beckett M, Fernandez C, et al. Tumor-reprogrammed resident T cells resist radiation to control tumors[J]. Nat Commun, 2019, 10(1): 3959. DOI: 10.1038/s41467-019-11906-2. pmid: 31477729
[28]	Wegner RE, Abel S, D'Amico RS, et al. Time from stereotactic radiosurgery to immunotherapy in patients with melanoma brain metastases and impact on outcome[J]. J Neurooncol, 2021, 152(1): 79-87. DOI: 10.1007/s11060-020-03663-w.
[29]	Ferris RL, Moskovitz J, Kunning S, et al. Phase Ⅰ trial of cetu-ximab, radiotherapy, and ipilimumab in locally advanced head and neck cancer[J]. Clin Cancer Res, 2022, 28(7): 1335-1344. DOI: 10.1158/1078-0432.CCR-21-0426.
[30]	Savage T, Pandey S, Guha C. Postablation modulation after single high-dose radiation therapy improves tumor control via enhanced immunomodulation[J]. Clin Cancer Res, 2020, 26(4): 910-921. DOI: 10.1158/1078-0432.CCR-18-3518. pmid: 31757878
[31]	Chen D, Verma V, Patel RR, et al. Absolute lymphocyte count predicts abscopal responses and outcomes in patients receiving combined immunotherapy and radiation therapy: analysis of 3 phase 1/2 trials[J]. Int J Radiat Oncol Biol Phys, 2020, 108(1): 196-203. DOI: 10.1016/j.ijrobp.2020.01.032.
[32]	Mirestean CC, Iancu RI, Iancu DT. Immunotherapy and radiotherapy—a future partnership focus on radiation induced lymphopenia (RIL) implications[J]. Bratisl Lek Listy, 2023, 124(1): 70-73. DOI: 10.4149/BLL_2023_011. pmid: 36519611
[33]	Patel JJ, Levy DA, Nguyen SA, et al. Impact of PD-L1 expression and human papillomavirus status in anti-PD1/PDL1 immunotherapy for head and neck squamous cell carcinoma—systematic review and meta-analysis[J]. Head Neck, 2020, 42(4): 774-786. DOI: 10.1002/hed.26036.
[34]	Galvis MM, Borges GA, Oliveira TB, et al. Immunotherapy improves efficacy and safety of patients with HPV positive and negative head and neck cancer: a systematic review and meta-analysis[J]. Crit Rev Oncol Hematol, 2020, 150: 102966. DOI: 10.1016/j.critrevonc.2020.102966.
[35]	Xu Y, Zhu G, Maroun CA, et al. Programmed death-1/programmed death-ligand 1-axis blockade in recurrent or metastatic head and neck squamous cell carcinoma stratified by human papillomavirus status: a systematic review and meta-analysis[J]. Front Immunol, 2021, 12: 645170. DOI: 10.3389/fimmu.2021.645170.
[36]	Sun XS, Michel C, Babin E, et al. Approach to oligometastatic disease in head and neck cancer, on behalf of the GORTEC[J]. Future Oncol, 2018, 14(9): 877-889. DOI: 10.2217/fon-2017-0468. pmid: 29578359
[37]	Gao Z, Zhao Q, Xu Y, et al. Improving the efficacy of combined radiotherapy and immunotherapy: focusing on the effects of radiosensitivity[J]. Radiat Oncol, 2023, 18(1): 89. DOI: 10.1186/s13014-023-02278-5. pmid: 37226275
[38]	Ali WAS, Huang X, Wu Y, et al. Pretreatment serum lactate dehydrogenase and metastases numbers as potential determinants of anti-PD-1 therapy outcome in nasopharyngeal carcinoma[J]. Cancer Control, 2023, 30: 10732748221148912. DOI: 10.1177/10732748221148912.
[39]	Qureshi HA, Zhu X, Yang GH, et al. Impact of HPV status on immune responses in head and neck squamous cell carcinoma[J]. Oral Oncol, 2022, 127: 105774. DOI: 10.1016/j.oraloncology.2022.105774.
[40]	Liu Z, Yu Z, Chen D, et al. Pivotal roles of tumor-draining lymph nodes in the abscopal effects from combined immunotherapy and radiotherapy[J]. Cancer Commun (Lond), 2022, 42(10): 971-986. DOI: 10.1002/cac2.12348.
[41]	Yura Y, Hamada M. Oral immune-related adverse events caused by immune checkpoint inhibitors: salivary gland dysfunction and mucosal diseases[J]. Cancers (Basel), 2022, 14(3): 792. DOI: 10.3390/cancers14030792.